Q3 2025 Management View CEO Aric Coffman described 2025 as a “transitional year, one focused on improving stability, strengthening operating discipline and maturing the clinical foundation of the ...

Kyverna Therapeutics (KYTX) is rated a strong buy with promising KYV-101 Phase 2 data and near-term catalysts. Read here for ...

Submission packages—such as drug master files for active ingredients—are pre-validated by an AI engine, allowing companies to ...

The rapid expansion of AI has caught many CISOs off guard as they scramble to adapt existing security solutions to the new ...

Over the long term, private equity returns have outpaced those from public markets. This strength can be attributed to a ...

Operator: Good afternoon, ladies and gentlemen, and welcome to the CytoSorbents Corp. Third Quarter 2025 Earnings Conference ...